RCAN1 regulates vesicle recycling and quantal release kinetics via effects on calcineurin activity by Zanin, Mark Phillip et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
This is the authors’ version of an article published in 
Journal of Neurochemistry. The original publication is 
available by subscription at: 
http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%
291471-4159 
doi: 10.1111/jnc.12086
Please cite this article as: 
Zanin MP, Mackenzie KD, Peiris H, Pritchard MA, Keating 
DJ. RCAN1 regulates vesicle recycling and quantal release 
kinetics via effects on calcineurin activity. Journal of 
Neurochemistry. (2013)124: 290–299
Copyright (2013) © 2012 International Society for 
Neurochemistry. All rights reserved. Please note that any 
alterations made during the publishing process may not 
appear in this version. 
RCAN1 regulates vesicle recycling and quantal release kinetics via effects on 
calcineurin activity. 
Mark P. Zanin1, Kimberly D. Mackenzie1, Heshan Peiris1, Melanie A. Pritchard2 and 
Damien J. Keating1 
1Discipline of Human Physiology and Centre for Neuroscience, Flinders University, 
Australia and 2 Department of Biochemistry and Molecular Biology, Monash 
University, Australia. 
Proofs and reprint requests should be addressed to: 
Dr Damien Keating  
Department of Human Physiology, Flinders University 
Sturt Rd, Bedford Park, Adelaide, South Australia, 5042, Australia. 
Phone: +61 8 8204 4282  
Fax: +61 8 8204 5768 
Email: damien.keating@flinders.edu.au 
Running title: RCAN1 controls vesicle release 
Keywords: exocytosis, quantal release, chromaffin cell, amperometry, endocytosis 
Abstract 
We have previously shown that Regulator of Calcineurin 1 (RCAN1) regulates 
multiple stages of vesicle exocytosis. However, the mechanisms by which RCAN1 
affects secretory vesicle exocytosis and quantal release kinetics remain unknown. 
Here we use carbon fiber amperometry to detect exocytosis from chromaffin cells 
and identify these underlying mechanisms. We observe reduced exocytosis with 
repeated stimulations in chromaffin cells overexpressing RCAN1 (RCAN1ox), but not 
in wild type (WT) cells, indicating a negative effect of RCAN1 on vesicle recycling 
and endocytosis. Acute exposure to calcineurin inhibitors, cyclosporine A and FK-
506, replicates this effect in WT cells but has no additional effect in RCAN1ox cells. 
When we chronically expose WT cells to cyclosporine A and FK-506 we find that 
catecholamine release per vesicle and pre-spike foot (PSF) signal parameters are 
decreased, similar to that in RCAN1ox cells. Inhibiting calcineurin activity in RCAN1ox 
cells has no additional effect on the amount of catecholamine release per vesicle but 
further reduces PSF signal parameters. Electron microscopy studies indicate these 
changes are not due to altered vesicle number or distribution in RCAN1ox cells but 
reduced vesicle release may be cause by decreased vesicle and dense core size in 
RCAN1ox cells. Thus, our results indicate that RCAN1 may negatively affects vesicle 
recycling and quantal release kinetics via the inhibition of calcineurin activity.   
 
Introduction 
Regulator of Calcineurin 1 (RCAN1) is a chromosome 21 gene that is over expressed 
in Down syndrome (DS) and Alzheimer’s disease (AD) brains (Ermak et al. 2001, 
Fuentes et al. 2000). Human DS and AD brains demonstrate neuronal changes 
including reduced noradrenaline signalling, basal forebrain cholinergic neuron 
degeneration, enlarged endosomes and dementia (Lai et al. 1999). Mouse models of 
both disorders demonstrate reduced synaptic transmission, LTP and altered learning 
and memory (Oddo et al. 2003, Siarey et al. 2005). Identifying proteins common to 
both DS and AD which have roles in cell signalling or neurotransmitter release may 
enhance our understanding of the mechanisms underlying the neuronal changes 
observed in these disorders.  
 
We have previously identified RCAN1 as a novel regulator of vesicle release and 
quantal release kinetics (Keating et al. 2008). These experiments were undertaken in 
mouse adrenal chromaffin cells using carbon fibre amperometry, a method which 
measures the number of individual vesicles undergoing exocytosis and the amount 
released from each vesicle. Additionally, exocytotic events in these cells are often 
associated with a pre-spike “foot” (PSF) signal that represents release of 
catecholamine during the formation of a stable fusion pore. We previously illustrated 
that altering RCAN1 expression reduces the number of exocytotic events occurring in 
chromaffin cells (Keating et al. 2008). We also observe that increased levels of 
RCAN1 reduced the amount released from individual vesicles and decreased PSF 
signal duration (Keating et al. 2008). These effects do not appear to be due to 
changes in vesicle loading or size, alterations in Ca2+ entry or the size of the readily 
releasable pool of vesicles.   
 
The most well characterised role of RCAN1 is as an inhibitor of calcineurin activity 
(Fuentes et al. 2000, Kingsbury et al. 2000, Rothermel et al. 2000). There are several 
potential mechanisms by which RCAN1 might regulate exocytosis and quantal 
release kinetics via its effects on calcineurin activity. Reduced calcineurin activity 
caused by RCAN1 overexpression could alter the phosphorylation and activity of a 
number of calcineurin targets involved in exocytosis and vesicle recycling such as 
Munc18 (Craig et al. 2003), dynamin 1, amphiphysin 1/2 and synaptojanin (Cousin & 
Robinson 2001). Such an explanation focuses on the effect that relatively acute 
alterations in calcineurin activity could have on these processes. Chronic alterations 
in calcineurin activity may also have transcriptional effects via the well-characterised 
calcineurin/NFAT signalling node, which regulates presynaptic neurotransmitter 
release (Freeman et al. 2011). RCAN1 may also affect exocytosis and quantal 
release kinetics via direct mechanisms that are independent of its effect on 
calcineurin activity.  
 
Here we identify the role of calcineurin activity associated with the regulation of 
exocytosis by RCAN1. Increased RCAN1 expression reduces vesicle endocytosis 
and recycling in a repeated stimulation protocol and this effect is caused by the 
inhibition of calcineurin in cell overexpressing RCAN1. Chronic (3 days in vitro) 
calcineurin inhibition in WT cells replicates the changes in quantal release kinetics 
observed in RCAN1ox cells and such calcineurin inhibition has no additional effect of 
the amount of catecholamine released per vesicle in RCAN1ox cells. This treatment in 
RCAN1ox cells does, however, have further effect on PSF signal kinetics illustrating 
an effect of RCAN1 on early quantal release stability that is independent of its effects 
on calcineurin activity. Electron microscopy confirms that RCAN1 overexpression 
does not affect vesicle distribution or morphology in chromaffin cells. Therefore, 
increased RCAN1 expression inhibits calcienrin activity to negatively effect the 
amount of vesicle content released as well as affects vesicle endocytosis and 
recycling.  
 
Materials and Methods 
 
Chromaffin cell culture 
Adrenal glands were taken from 6-8 week-old male wild type (WT) and RCAN1ox 
mice and chromaffin cells were prepared as previously (Keating et al. 2008) as 
approved by the Flinders University Animal Welfare Committee. Briefly, the adrenal 
medulla was dissected out in cold Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 3.6 
mM NaHCO3, 5.6 mM glucose, 5.0 mM HEPES, pH 7.4) and then incubated with 
collagenase type A (Roche, Germany) in Locke’s buffer at a concentration of 3 mg/ml 
in a shaking bath at 37oC. The collagenase was diluted further in cold Locke’s buffer, 
cells pelleted and resuspended in cell culture medium (DMEM medium 
supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen, 
Carlsbad, CA, USA), 2mM L-glutamine (Invitrogen, Carlsbad, CA, USA) and 10% 
FCS (JRH Biosciences, Lenexa, USA)) and filtered through nylon mesh. Cells were 
pelleted, resuspended in supplemented DMEM and plated on 35 mm culture dishes 
and incubated at 37oC with 5% CO2. Cells were maintained in primary culture for 3 to 
4 days prior to experiments. 
 
Carbon Fiber Amperometry 
Catecholamine release from single chromaffin cells was measured using 
amperometry (Maritzen et al. 2008, Yu et al. 2008). A carbon fibre electrode 
(ProCFE, Dagan Corporation, USA) was placed on a chromaffin cell and +800 mV 
applied to the electrode under voltage clamp conditions. Current due to 
catecholamine oxidation was recorded using an EPC-9 amplifier and Pulse software 
(HEKA Electronic, Germany), sampled at 10 kHz and low-pass filtered at 1 kHz. For 
quantitative analysis, files were converted to Axon Binary Files (ABF Utility, version 
2.1, Synaptosoft, USA) and secretory spikes analysed (Mini Analysis, version 6.0.1, 
Synaptosoft, USA) for a period of 60s from the start of stimulation. The standard bath 
solution (Krebs buffer) contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1mM MgCl2, 
5mM D-glucose, 10 mM HEPES, pH 7.4. High K+-containing solution was the same 
as the control bath solution except that 70 mM K+ replaced an equimolar amount of 
NaCl. All solutions were applied to cells using a gravity perfusion system, the outlet 
of which was placed within 500µm from the recorded cell. All experiments were 
carried out at room temperature (22–24oC). Acute and chronic calcineurin inhibition 
experiments were conducted using solutions containing FK-506 (5μM) and 
cyclosporine A (5μM) (Sigma Australia). Acute treatments involved incubating cells 
with inhibitors in Krebs buffer for 5 minutes at room temperature prior to stimulations, 
which were then carried out in the presence of the inhibitors. Chronic inhibition 
treatment involved incubating chromaffin cells, prepared the previous day, in cell 
culture medium containing the inhibitors for 3 days at 37oC with 5% CO2. 
Stimulations were performed using Krebs buffers containing the inhibitors. 
 
Amperometry data analysis 
Data analysis was performed as previously described (Keating et al. 2008). Briefly, 
amperometric spikes were selected for analysis of event frequency if spike amplitude 
exceeded 10 pA and overlapping peaks were included. For kinetic analysis of spikes 
and PSF signals, only those events which exceeded 20 pA or were not overlapping 
with other spikes were included. Only pre-spike foot features longer than 1 ms and 
>2.5 times the RMS noise of the baseline in that recording were analyzed as foot 
signals.  
 
Electron microscopy 
Adrenal tissue was fixed and stained using a modified chromaffin reaction (Tranzer & 
Richards 1976). Adrenal glands were fixed for 6 hours at 4C in 0.1M phosphate 
buffer (PB) pH 7.2, containing 3% glutaraldehyde. The tissue was then transferred to 
0.1M PB, pH 7.2 and kept overnight at 4C. The samples were washed 3 times in 
0.1M PB before being post-fixed in 1% osmium tetroxide in 0.1M PB, pH 7.2 for 1hr 
at room temperature. After multiple washes the tissue was stained with 2% aqueous 
uranyl acetate for 30 minutes. Following a series of dehydration steps with ethanol 
solutions (50%-100%) and propylene oxide, the tissue was incubated for 1 hour in a 
1:1 mixture of propylene oxide: Durcupan resin (Sigma; Sigma-Aldrich Pty Ltd, Castle 
Hill, Australia). The samples were then embedded in pure resin in capsules and 
polymerization was carried out for 48 hours at 60C. An ultramicrotome (RMC 
Mechanical Advance Ultramicrotome) was used to cut thick sections (1µm) which 
were stained with 1% toluidine blue in 1% borax for light microscopic examinations. 
Ultrathin sections (80-100nm) were cut using a diamond knife (Diatome) and sections 
were mounted on single-slot copper grids which were coated with 0.6% - 0.8% 
Butvar solution in chloroform. The sections were then stained with Reynolds’ lead 
citrate solution (Reynolds 1963) and allowed to dry overnight. The ultra-thin sections 
were observed under transmission electron microscopy (JOEL1200-EX transmission 
electron microscope), and images were taken at 30,000 magnification. Ultrastructural 
images were captured with a Megaview3 camera using the ITEM interface program. 
Higher resolution montages of selected cells were compiled using the Multiple Image 
Alignment module in ITEM. 
 
Chromaffin granule counting and statistics 
Images were analyzed using ImageJ software (NIH). The number and spatial 
distribution of LDCVs were evaluated on micrographs covering the entire cell’s 
cytoplasmic region. LDCVs were identified by their electron-dense core and circular 
membrane. To measure vesicle localisation, 200 nm-wide concentric zones starting 
from the cell membrane were defined within each cell and the number of dense core 
vesicles within each region counted and presented as a percentage of the total 
number of vesicles. Dense core and vesicle diameter were measured from 50 
vesicles per cell. Representative regions within the cell were selected by overlaying a 
numbered grid on each electron micrograph. A random number generator was then 
used to identify the LDCV containing regions to be analysed. All electron 
micrographs taken at a magnification of  4000X and were analyzed using ImageJ 
image analysis software (NIH). 
 
Statistical analysis 
For amperometry whole spike analysis, as data is not parametrically distributed we 
obtain the median value in each recording and present the final data as the mean of 
these median values (Maritzen et al. 2008). This data is then analysed using a 
Student’s unpaired t-test. For PSF analysis we often do not obtain sufficient data 
points to use the median value from each recording. Therefore for these parameters 
we obtain the mean of each individual value and gauge statistical differences 
between the means of different groups using the Mann–Whitney test. All data are 
presented as mean ± SEM. For electron microscopy analysis, data is represented as 
the average number of LDCVs per unit area ± SEM. Data for each genotype was 
compared using a Student’s unpaired t-test. In all statistical tests significance was 
obtained at p<0.05. 
 
Results 
 
RCAN1 overexpression does not alter vesicle localisation in chromaffin cells  
We have previously demonstrated changes in exocytosis in RCAN1ox chromaffin 
cells (Keating et al. 2008). We therefore used electron microscopy to analyse 
whether changes in exocytosis in RCAN1ox cells may be due to alterations in vesicle 
number and localisation. The ultrastructural appearance of WT (Figure 1A) and 
RCAN1ox (Figure 1B) chromaffin cells appears similar and we find that the average 
number of vesicles per unit area is not different between WT (n=7 cells) and 
RCAN1ox cells (n=9 cells, Figure 1C). We also assessed the distribution of vesicles 
with regard to their distance from the plasma membrane in these cells. We find no 
differences in the average distance from the membrane between WT and RCAN1ox 
cells (Figure 1D). These results indicate that altered exocytosis in RCAN1ox 
chromaffin cells is not due to altered vesicle number or distribution. We additionally 
measured vesicle size in these cells and observe a significant decrease both in mean 
vesicle diameter (Figure 1E, p<0.001) and dense core diameter (Figure 1F, p<0.001). 
This data indicates that catecholamine loading into vesicles is negatively affected in 
RCAN1ox chromaffin cells. 
 
RCAN1 regulates vesicle recycling in chromaffin cells by inhibiting calcineurin. 
Calcineurin controls endocytosis primarily through regulation of the activity of the 
endocytic proteins known as the dephosphins (Cousin & Robinson 2001). As 
endocytosis and exocytosis are directly interlinked, we wished to know whether 
endocytosis and vesicle recycling defects might underlie reduced levels of exocytosis 
in RCAN1ox cells. To gauge this we implemented a repeated stimulations protocol, 
consisting of three one-minute stimulations with 5 minute intervals between them that 
reflects the release of vesicles that have been endocytosed in a dynamin-dependent 
manner after the initial stimulation (Elhamdani et al. 2001). This protocol induces 
consistent levels of exocytosis in WT cells (Figure 2A-D). However when we acutely 
inhibit calcineurin activity in WT cells using the calcineurin inhibitors cyclosporine A 
and FK-506, the result is a decline (P<0.05) in the number of vesicles undergoing 
exocytosis during subsequent stimulations (Figure 2E-H). This indicates that 
calcineurin controls vesicle recycling in WT chromaffin cells and that acute exposure 
to known inhibitors of calcineurin activity causes a rundown of secretion with this 
repeated stimulation protocol. We repeated these experiments in RCAN1ox 
chromaffin cells. RCAN1ox cells display a rundown in exocytosis in the absence of 
any calcineurin inhibitors using this protocol (Figure 3A-D), indicative of a recycling 
defect in RCAN1ox chromaffin cells. Importantly, acute exposure to inhibitors of 
calcineurin in RCAN1ox cells has no additional effect on vesicle recycling compared 
to RCAN1ox cells in the absence of these inhibitors (Figure 3E-H). These results 
therefore support the possibility that calcineurin activity controls vesicle recycling in 
chromaffin cells and that RCAN1 overexpression in RCAN1ox cells may inhibit vesicle 
recycling due to reduced activity of calcineurin. 
 
 
Repeated acute inhibition of calcineurin does not alter quantal release kinetics. 
Our previous studies identified a role for RCAN1 in the regulation of the amount of 
catecholamine released from individual vesicles and that this change was not 
replicated when we acutely inhibited calcineurin and stimulated cells a single time 
(Keating et al. 2008). However, we find in the present study that vesicle recycling is 
reduced following repeated stimulations in the presence of calcineurin inhibitors. We 
hypothesise that this is due to altered dephosphorylation of calcineurin target 
proteins involved in vesicle fission and fusion. As the phosphorylation status of some 
exocytosis proteins, such as Munc-18 (Craig et al. 2003), is affected by calcineurin 
activity, we therefore wished to identify if quantal release kinetics are also affected 
during this repeated stimulations protocol in the presence of cyclosporine A and FK-
506. We therefore analysed the spike kinetics from the previous experiments in 
which we acutely exposed cells to cyclosporine A and FK-506 for 10 minutes in WT 
cells and repeatedly stimulated cells in the continued presence of these drugs. We 
find that this has no effect on vesicle release kinetics such as amperometric spike 
area (Figure 4A), rise time (Figure 4B), half-width (Figure 4C) or decay time (Figure 
4D). Therefore, short-term exposure to calcineurin inhibitors, even during repeated 
stimulations, does not affect quantal release kinetics and the amount of 
catecholamine released per vesicle.   
 
RCAN1 overexpression may reduce the amount released per vesicle via the chronic 
inhibition of calcineurin activity. 
As calcineurin activity is thought to be chronically, rather than acutely, inhibited in 
RCAN1ox cells, we next investigated whether chronic exposure to calcineurin 
inhibitors could explain the effect of RCAN1 overexpression on vesicle release in 
RCAN1ox chromaffin cells. We cultured chromaffin cells for 3 days in the presence or 
absence of cyclosporine A and FK-506 and compared the effect on amperometric 
spike kinetics in both WT and RCAN1ox cells. Chronic exposure to calcineurin 
inhibitors reduced the total amount of catecholamine released per vesicle in WT cells 
(Figure 5A). Unsurprisingly therefore,  the rise time (Figure 5B), half-width (Figure 
5C) and decay time (Figure 5D) of WT spikes were also changed during chronic 
exposure to cyclosporine A and FK-506. When we undertook these experiments in 
RCAN1ox cells we observe the reduced release from vesicles that we previously 
published (Keating et al. 2008). Importantly, when we chronically exposed RCAN1ox 
cells to cyclosporine A and FK-506 we observe no additional decrease in these spike 
parameters. Thus it is possible that chronic inhibition of calcineurin activity reduces 
quantal release kinetics and that the reduced amount of catecholamine released from 
RCAN1ox vesicles may be due to chronic inhibition of calcineurin caused by RCAN1 
overexpression. 
 
Calcineurin activity may also be important for regulating release during the earliest 
stages of exocytosis.  
In amperometric recordings, a pre-spike foot (PSF) signal is often observed before a 
full secretory spike. This PSF represents the release of catecholamine through the 
developing fusion pore as it transitions to a stable, fully dilated pore. As we 
previously reported reductions in the PSF signal (Keating et al. 2008) when RCAN1 
is overexpressed, we analysed changes in the PSF signal in WT and RCAN1ox cells 
when cells are chronically exposed to cyclosporine A and FK-506. In WT cells we 
observe no change in PSF signal amplitude when cells are exposed to these drugs 
(Figure 6A) but do observe significant decreases in PSF signal duration (P<0.001, 
Figure 6B) and area (P<0.001, Figure 6C). In RCAN1ox cells, chronic calcineurin 
inhibition caused a significant decrease in PSF signal duration (P<0.001) and area 
(P<0.01).  
 
Discussion 
 
We have previously shown that RCAN1 is a regulator of exocytosis and is involved in 
the regulation of both the amount of catecholamine released from vesicles and the 
number of vesicles undergoing fusion (Keating et al. 2008). In the present study we 
reveal further insights into the role of RCAN1 in the regulation of exocytosis. We 
firstly identify that overexpression of RCAN1 and the acute use of pharmacological 
agents which inhibit calcineurin activity both reduce vesicle recycling and re-use. 
Furthermore the combination of these two treatments has no additive effect in our 
vesicle recycling assay. These effects are not caused by changes in vesicle number 
or distribution as evidenced from our electron microscopy studies. Short term 
(minutes) use of drugs known to inhibit calcineurin activity does not affect the amount 
of catecholamine released per vesicle during our repeated stimulation protocol. 
However when we chronically (days) expose cells to these calcineurin inhibitors, as 
would occur if RCAN1 overexpression were inhibiting calcineurin in RCAN1ox cells, 
we find the amount of catecholamine released from single vesicles to be drastically 
reduced to a simlar level to that seen in RCAN1ox cells. Our finding that the chronic 
use of calcineurin inhibitors does not have any additional effect on vesicle release in 
RCAN1ox cells suggests that RCAN1 overexpression in these cells reduces quantal 
vesicle release via the inhibition of calcineurin activity. Our EM analysis further 
illustrates that the underlying mechanism explaining reduced vesicle release in 
RCAN1ox cells is a reduced catecholamine loading into vesicles. Intriguingly however, 
we still observe an effect of cyclosporine A and FK-506 in RCAN1ox cells on the PSF 
signal. 
 
The progressive decrease in exocytosis observed with our repeated stimulation 
protocol in the presence of cyclosporine A and FK506 suggests that vesicle 
endocytosis and recycling are impaired when calcineurin activity is blocked. This 
result is identical to the effect of dynamin inhibition in chromaffin cells using the same 
protocol (Elhamdani et al. 2001) and indicates the protocol provides a measurement 
of vesicle recycling and re-use in these cells. Overexpression of RCAN1 induces the 
same decrease in vesicle recycling. The lack of any further effect with 
pharmacological calcineurin inhibition indicates that RCAN1 overexpression may be 
inhibiting calcineurin activity to reduce recycling and re-use in subsequent 
stimulations. A likely mechanism underlying this is inhibition of the dephosphins, the 
group of structurally diverse proteins that are essential for vesicle endocytosis and 
which are all dephosphorylated by calcineurin. These proteins include dynamin, 
amphiphysin 1 and 2, synaptojanin, AP180, Epsin and Eps15 (Cousin & Robinson 
2001).   
 
We also tested whether spike kinetics are affected by RCAN1 overexpression or 
calcineurin inhibition during these repeated stimulations experiments. In these 
experiments we hypothesised that reduced calcineurin activity, which was potentially 
causing changes in endocytosis, may also affect quantal release kinetics. The 
phosphorylation state of most exocytosis proteins, including SNARE proteins, affects 
their function, and subsequently the kinetics of vesicle release. For example, 
Munc18-1 binds to syntaxin 1 with higher affinity when dephosphorylated by 
calcineurin (Craig et al. 2003). Therefore, if calcineurin activity is decreased in 
RCAN1ox cells, Munc18-1 may bind to syntaxin1 with lower affinity, resulting in 
unstable fusion pore formation and accelerated fusion pore kinetics. Acceleration of 
fusion pore kinetics as a result of decreased Munc18 phosphorylation has been 
previously demonstrated (Barclay et al. 2003) using Munc18 phosphomimetic 
mutations. The lack of effect on vesicle release kinetics by acute exposure to 
cyclosporine A and FK-506 indicates that short term calcineurin inhibition, even 
during repeated stimulation, does not alter vesicle release.  
 
Our experiments in which we chronically inhibit calcineurin activity in WT cells are the 
first example illustrating that this enzyme may control vesicle release kinetics. This 
effect may be due to changes in phosphorylation state of Munc18 or other exocytosis 
proteins as discussed or alternatively, longer term exposure to cyclosporine A and 
FK-506 may affect release due to changes in gene transcription that take longer than 
the total 10-30 minute duration of the acute inhibition experiments. Calcineurin is able 
to affect transcription through the NFAT transcription pathway (Clipstone & Crabtree 
1992). Loss of NFAT function in pancreatic β-cells causes hypoinsulinemia due to 
downregulation of insulin gene transcription and insulin synthesis (Heit et al. 2006). 
NFAT also regulates activity-dependent plasticity in Drosophila (Freeman et al. 2011) 
and NFAT-dependent transcription controls both morphological and 
electrophysiological properties of neurons (Schwartz et al. 2009). As amperometry 
measures only the release of oxidisable catecholamines, we cannot be sure if altered 
fusion pore kinetics underlie the reduced catecholamine release from individual 
vesicles or whether such changes are due to factors affecting the amount of 
catecholamine packaged inside each vesicle. Our electron microscopy results 
demonstrating a decrease in dense core volume in RCAN1ox cells clearly point 
towards a defect in catecholamine loading in these cells and would argue against an 
effect on fusion pore kinetics. Global gene expression analysis may provide useful 
information regarding potential transcriptional changes occurring in RCAN1ox 
chromaffin cells and whether transcriptional changes affect various secretion-
associated processes.  
 
While we observe no  effect of chronic exposure to cyclosporine A and FK506 on 
single vesicle catecholamine release in RCAN1ox cells, effects on PSF signal 
duration and area do occur. The PSF signal represents catecholamine flux through 
the transient, unstable fusion pore as it transitions to an open, stable full fusion pore 
(Zhang & Jackson 2010, Zhou et al. 1996). Our results present at least two intriguing 
possibilities. Firstly, RCAN1 may have a direct effect on the earliest stages of fusion 
pore formation independent of its role as a calcineurin inhibitor. There are currently 
no identified protein binding partners of RCAN1 which might explain such an effect. 
RCAN1 contains two proline-rich domains (Fuentes et al. 1995) which typically bind 
to SH3 regions. SH3 regions are contained in a number of proteins associated with 
vesicle trafficking, exocytosis and endocytosis including ITSN1 and amphiphysin 1 
and 2 (Keating et al. 2006) but whether such interactions occur or even regulate 
fusion pore development is an area of future investigation. Secondly, RCAN1 
overexpression in these cells may not fully inhibit calcineurin and only when 
calcineurin is completely inhibited pharmacologically do we see the full effect of 
cyclosporin A and FK506 on the PSF signal. There may therefore be differences in 
calcineurin sensitivity associated with the mechanisms underlying the amount 
released per vesicle (spike area) compared to the regulation of the PSF signal. 
 
It must also be noted that the calcineurin inhibitors used in this study have effects 
other than calcineurin inhibition. In order to competitively bind to and inhibit 
calcineurin activity cyclosprine A forms complexes with cyclophilin D while FK506 
complexes with FK506 binding protein (FKBP) (Liu et al. 1991). Cyclophilin D can 
also bind the mitochondrial permeability transition pore to effect mitochondrial 
function (Elrod et al. 2010) while FK506 reduces the peptidyl-prolyl isomerase activity 
of FKBP (Brecht et al. 2003). Thus, while calcineurin inhibition is the primary 
therapeutic effect of these immunosuppressants, it is possible that the changes in 
secretion we observe with these drugs could be independent of changes in 
calcineurin activity. However, given the lack of additive effect on vesicle recycling and 
quantal vesicle release when we overexpress an endogenous calcineurin inhibitor 
(RCAN1) and add known calcineurin inhibitors, our primary conclusion is that these 
treatments affect secretion through the same mechanism by reduced calcineurin 
activity. 
 
In summary, our results demonstrate that RCAN1 regulates cell communication at 
several stages. Endocytosis and vesicle re-use as well as vesicle release is 
controlled by RCAN1 as well as by pharmacological calcineurin inhibitors, likely 
through the same mechanism of action of reduced calcineurin activity. What the sites 
of calcineurin/RCAN1 are in these instances remains to be identified. The reduction 
in vesicle size and catecholamine loading observed in our EM experiments seem to 
explain the decreased catecholamine release per vesicle in RCAN1ox cells. 
Catecholamine release through the developing fusion pore is additionally affected by 
RCAN1. This effect of RCAN1 may be either be independent of the inhibitory action 
of RCAN1 on calcineurin or be explained by a differential sensitivity to calcineurin 
activity between early and full fusion release. Our data therefore reveals a role of 
RCAN1 in regulating exocytosis at several stages. Recently published data illustrates 
that changes in hippocampal structure and function occur in these RCAN1ox mice 
brains (Martin et al. 2012). However these changes may not be associated with 
alterations in calcineurin activity and involve instead changes directly associated with 
RCAN1 function. Therefore, while increased expression of RCAN1 may play a 
significant role in the cognitive and neuronal pathologies associated with Alzheimer’s 
disease and Down syndrome, elucidating which of these are associated with the role 
of RCAN1 as an inhibitor of calcineurin needs to be clearly defined and may well vary 
for individual types of cells or neurons. This point is further highlighted by recent 
evidence demonstrating that the effects of RCAN1 on calcineurin are dependent on a 
number of factors including the degree of RCAN1 expression and the presence of 
other RCAN1-bidning partners that effect the relationship between RCAN1 and 
calcineurin (Liu et al. 2009). 
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Figure 1: RCAN1 overexpression does not alter vesicle number or localisation. A 
representative electron micrograph of an adrenal medulla section from (A) WT and 
(B) RCAN1ox mice clearly shows the large dense core vesicles throughout each 
chromaffin cell. The red line indicates the plasma membrane of a single chromaffin 
cell. (C) The average number of large dense core vesicles per unit area is not 
different nor is (D) the localisation of vesicle from the plasma membrane. (E) Vesicle 
diameter and (F) dense core diameter are significantly smaller in RCAN1ox 
chromaffin cells indicating reduced catecholamine storage in RCAN1ox vesicles. N=3 
animals per genotype and n=7 and 9 different cells from WT and RCAN1ox mice, 
respectively, ***p<0.001. 
  
 
 
Figure 2: Calcineurin inhibition reduces exocytosis during repeated stimulations.  
Cells were stimulated 3 successive times for 1 minute with 5 minutes rest between 
stimulations (Elhamdani et al. 2001). In WT cells we observe similar levels of 
exocytosis between the first (A), second (Β) and third (C) stimulations. (D) The 
average number of exocytotic events does not decrease with this protocol (n=6 
cells). Repeating these experiments in the acute presence of the calcineurin 
inhibitors, cyclosporine A and FK-506 results in exocytotic events (E) that reduce in 
frequency with a second (F) and third (G) stimulation. (H) This reduction was 
significant upon the second and third stimulations (H, n=16 cells, *p<0.05).  
  
 
 
Figure 3: Exocytosis rundown occurs in RCAN1ox cells with no additional effect of 
acute calcineurin inhibition. Cells were stimulated 3 successive times for 1 minute 
with 5 minutes rest between stimulations (Elhamdani et al. 2001). In RCAN1ox cells 
we observe a gradual decline in exocytosis between the first (A), second (Β) and 
third (C) stimulations. (D) The average number of exocytotic events significantly 
decreases with this protocol (n=7 cells, *p<0.05, **p<0.01). Repeating these 
experiments in the acute presence of the calcineurin inhibitors, cyclosporine A and 
FK-506 also results in exocytotic events (E) and these reduce in frequency with a 
second (F) and third (G) stimulations. (H) This reduction was significant upon the 
second and third stimulations (H, n=4 cells, *p<0.05, **p<0.01).  
 
Figure 4: Repeated stimulation of WT chromaffin cells during acute calcineurin 
inhibition does not affect vesicle release kinetics. While acute calcineurin inhibition 
during repeated stimulations causes reduced exocytosis rates, it does not affect 
amperometric spike (A) area, (B) rise time, (C) half-width or (D) decay time (n=16 
cells) when comparing these parameters between the first (white bar), second 
(horizontal stripes) and third (vertical stripes) stimulation. 
  
 
 
Figure 5: Chronic calcineurin inhibition underlies the altered quantal release kinetics 
observed in RCAN1ox chromaffin cells. Cells were treated for 4-6 days in culture with 
calcineurin inhibitors, cyclosporine A and FK-506 (5 µM, indicated by + CaN 
inhibition). In WT cells this resulted in significant reductions in (A) spike area, (B) rise 
time, (C) half-width and (D) decay time. However this caused no change in these 
parameters in RCAN1ox cells. *P<0.05, **P<0.01 In WT n=11 control conditions and 
17 under calcineurin inhibition. In RCAN1ox n=11 in control and 10 under calcineurin 
inhibition. 
  
 
 
Figure 6: Chronic calcineurin inhibition reduces aspects of the PSF signal in both 
WT and RCAN1ox cells. From the same experiments as those shown in Figure 4, we 
observe that chronic calcineurin inhibition has (A) no effect on PSF amplitude in WT 
or RCAN1ox cells but decreases both (B) PSF signal duration and (C) PSF signal 
area in WT and RCAN1ox cells. **P<0.01, ***P<0.001 In WT n=207 spikes in control 
conditions and 285 under calcineurin inhibition. In RCAN1ox n=287 spikes in control 
and 166 under calcineurin inhibition. 
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